Bio-Rad Unveils Vitamin-D Test in International Market - Analyst Blog

Bio-Rad Laboratories, Inc. BIO reported the launch of the BioPlex 2200 25-OH Vitamin D kit, which will be used in the company's BioPlex 2200 system. For now, the company has launched the kit only in the international market.

The assay provides a fully-automated method for the quantitative measurement of total 25-hydroxy vitamin D in human serum. The 25-hydroxy vitamin D test is the most accurate way to determine the amount of vitamin D present in an individual's body.

A Brief Note about Vitamin D Testing

Vitamin D, a fat-soluble organic component that promotes absorption and metabolism of calcium and phosphorus in one's body, plays a crucial role in maintaining one's bone health. Recently, a number of studies validated associations between Vitamin D deficiency and an increased risk of cardiovascular disease, autoimmune disease, and cancer.

As a result, physicians nowadays include Vitamin D testing as part of the routine assessment of their patients' overall health. This has led to substantial growth in the Vitamin D testing market, over the past several years.

Per management at Bio-Rad, the aforementioned Vitamin D kit has the potential to amplify the company's portfolio of autoimmune and infectious disease analyses.

What is BioPlex 2200 System?

Bio-Rad's BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system used for clinical diagnostic analyses that enables the detection and quantification of multiple analytes – proteins and peptides, or nucleic acids – in a single sample volume.

This system provides clinical laboratories with the capability to rapidly process multiple individual tests that are traditionally processed separately. The Bio-Plex multiplex system can multiplex up to 500 different tests simultaneously.

Zacks Rank

Bio-Rad currently has a Zacks Rank #5 (Sell). Some better-ranked medical product stocks that warrant a look are OraSure Technologies, Inc. OSUR, Cardica Inc. CRDC, and ICU Medical, Inc. ICUI. While OraSure sports a Zacks Rank #1 (Strong Buy), Cardica and ICU Medical hold a Zacks Rank #2 (Buy).      



 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CARDICA INC CRDC: Free Stock Analysis Report
 
ORASURE TECH OSUR: Free Stock Analysis Report
 
BIO-RAD LABS -A BIO: Free Stock Analysis Report
 
ICU MEDICAL INC ICUI: Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research